Anshul Maheshwari Sells 5,304 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 5,304 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the sale, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. This represents a 2.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, November 18th, Anshul Maheshwari sold 2,439 shares of SI-BONE stock. The stock was sold at an average price of $12.68, for a total value of $30,926.52.

SI-BONE Stock Performance

SI-BONE stock opened at $14.15 on Wednesday. The business has a 50 day moving average of $13.63 and a 200-day moving average of $14.17. The company has a market capitalization of $593.42 million, a P/E ratio of -15.38 and a beta of 1.16. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $21.64. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SIBN shares. Truist Financial increased their target price on shares of SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of SI-BONE in a research note on Wednesday, November 20th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE currently has an average rating of “Buy” and a consensus target price of $23.00.

Hedge Funds Weigh In On SI-BONE

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in shares of SI-BONE by 14.7% in the third quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company’s stock worth $2,486,000 after purchasing an additional 22,732 shares during the last quarter. Franklin Resources Inc. grew its position in shares of SI-BONE by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock valued at $265,000 after buying an additional 1,745 shares during the last quarter. Barclays PLC increased its stake in shares of SI-BONE by 190.8% in the third quarter. Barclays PLC now owns 96,623 shares of the company’s stock valued at $1,350,000 after buying an additional 63,402 shares during the period. Geode Capital Management LLC raised its position in shares of SI-BONE by 3.4% during the third quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock worth $12,921,000 after acquiring an additional 30,005 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of SI-BONE in the third quarter worth approximately $448,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.